Chengdu Olymvax Biopharmaceuticals Inc.

688319

CNE1000051H8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-25 EDT			5-day change	1st Jan Change
9.64 ^CNY	+2.01%		-0.21%	-38.99%

05-16	Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials	MT
04-25	Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Chengdu Olymvax Biopharmaceuticals Inc. has completed an IPO in the amount of CNY 400.4 million.

May 31, 2021 at 12:00 am

Chengdu Olymvax Biopharmaceuticals Inc. has completed an IPO in the amount of CNY 400.4 million.

Security Name: A Shares
Security Type: Common Stock
Securities Offered: 40,530,000
PriceRange: CNY 9.879102

Latest news about Chengdu Olymvax Biopharmaceuticals Inc.

Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials	05-16	MT
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Olymvax Biopharmaceuticals Withdraws Application for Combined Influenza Vaccine	02-02	MT
Olymvax Biopharmaceuticals Grants Keyuan Xinhai Marketing Rights for Meningococcal Vaccines	12-12	MT
Olymvax Biopharmaceuticals to Push Through Phase III Trial Into Recombinant Staphylococcus Aureus Vaccine	11-21	MT
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Chengdu Olymvax Biopharmaceuticals Inc.(XSSC:688319) added to S&P Global BMI Index	23-09-18	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-17	CI
Chinese healthcare stocks hit by stepped up anti-graft crackdown	23-08-09	RE
Olymvax Biopharma Gets Nod to Amend Packaging of Adsorbed Tetanus Vaccine	23-07-12	MT
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-17	CI
Chengdu Olymvax Biopharmaceuticals Inc.(SHSE:688319) added to Shanghai Stock Exchange A Share Index	22-06-08	CI
Chengdu Olymvax Biopharmaceuticals Inc.(SHSE:688319) added to Shanghai Stock Exchange Composite Index	22-06-08	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-22	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Chengdu Olymvax Biopharmaceuticals Inc. has completed an IPO in the amount of CNY 400.4 million.	21-05-31	CI
Chengdu Olymvax Biopharmaceuticals Inc. has filed an IPO.	20-06-21	CI

Chart Chengdu Olymvax Biopharmaceuticals Inc.

Duration

Period

Chart Chengdu Olymvax Biopharmaceuticals Inc.

More charts

Company Profile

Chengdu Olymvax Biopharmaceuticals Inc is a China-based biopharmaceutical company mainly engaged in the research, development, production and sales of human vaccines. The Company's products mainly include adsorbed tetanus vaccine, Hib conjugate vaccine and tetanus toxoid concentrate stock solution. The Company's main customers are center for disease control and prevention (CDC) customers.

Sector

Pharmaceuticals

Calendar

2024-08-15 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Chengdu Olymvax Biopharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.64

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CHENGDU OLYMVAX BIOPHARMACEUTICALS INC.	-38.99%	539M
CSL LIMITED	+2.97%	94.74B
SAMSUNG BIOLOGICS CO.,LTD.	-4.08%	37.28B
BIOGEN INC.	-13.26%	32.68B
UCB	+73.38%	27.72B
BIOMARIN PHARMACEUTICAL INC.	-11.58%	16.19B
INCYTE CORPORATION	-1.66%	13.88B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.67%	11.58B
ALTEOGEN INC.	+190.36%	10.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-52.61%	9.54B

Biopharmaceuticals